Clindamycin

Oral and parenteral products treat serious susceptible anaerobic infections and selected streptococcal, pneumococcal and staphylococcal infections. The labels reserve use when penicillin is unsuitable and less toxic alternatives are inappropriate. Listed sites include lower respiratory, skin/soft tissue, bloodstream, intra-abdominal and female pelvic infections; the injection also includes bone/joint infection. Obtain cultures/susceptibility when appropriate and use local resistance data. Clindamycin is unsuitable for meningitis because CSF penetration is inadequate.

Cleocin T solution, lotion and gel treat acne vulgaris; they are not oral or vaginal products. AAD’s public 2024 guidance recommends using acne antibiotics with benzoyl peroxide to limit resistance. Cleocin vaginal cream 2% treats diagnosed bacterial vaginosis, not Candida or other causes of vaginitis; evaluate competing pathogens.

This review covers the selected Cleocin formulations and routine intermittent systemic regimens. Specific MRSA, dental, endocarditis-prophylaxis, toxoplasmosis, malaria, pneumocystis or combination infection protocols are not implied by a broad antibacterial indication. Vaginal ovules, single-dose creams, other topical vehicles and fixed acne combinations need separate labels.

Capsules for children able to swallow them whole: serious infection 8–16 mg/kg/day, more severe 16–20 mg/kg/day, divided in 3 or 4 doses. The palmitate oral-solution label instead gives 8–12, 13–16 or 17–25 mg/kg/day for serious, severe or more severe infection, respectively, in 3 or 4 doses. It also lists 37.5 mg (2.5 mL) three times daily as a minimum to consider at body weight 10 kg or less; this legacy minimum is not a stand-alone infant prescription. Dose from total body weight even with obesity, verify severity/age and measure mL with an oral syringe. The solution is 75 mg/5 mL and can be taken with food. Do not transplant one product’s pediatric range to another.

Adults: 600–1200 mg/day for serious infections, or 1200–2700 mg/day for more severe infections, divided in 2, 3 or 4 doses. The label reports IV use up to 4800 mg/day in life-threatening situations; this is not a routine oral maximum. Children age 1 month–16 years: 20–40 mg/kg/day in 3 or 4 doses, based on total weight; its alternative body-surface regimens are 350 or 450 mg/m²/day by severity. Avoid IM doses above 600 mg per injection. Neonates require a specialist, exact preservative review and age-specific protocol; the source’s PMA headings/table overlap at 32 weeks, so no harmonized neonatal schedule is supplied here.

Concentrated vial solution must be diluted for IV use; it is not an IV bolus. IM vial administration is undiluted. Final IV concentration must not exceed 18 mg/mL and rate must not exceed 30 mg/min. Label examples: 300 mg in 50 mL over 10 minutes; 600 mg in 50 mL over 20; 900 mg in 50–100 mL over 30; 1200 mg in 100 mL over 40. More than 1200 mg in one 1-hour infusion is not recommended. ADD-Vantage is IV-only after the designated diluent preparation; GALAXY is premixed IV-only. Continuous-infusion serum-target protocols and neonatal tables are outside this concise dosing scope.

Cleocin T: thin film to affected skin twice daily; use pledgets once and discard. Shake lotion well immediately before use. Cleocin vaginal cream 2%: one 5 g applicator intravaginally, preferably at bedtime, for 3 or 7 days in nonpregnant patients and 7 days in pregnant patients per the selected label. CDC recommends the 7-day cream course; it lists oral clindamycin 300 mg twice daily for 7 days as an alternative BV regimen, which is professional guidance rather than the general capsule severity table.

Systemic beta-hemolytic streptococcal infection treatment is at least 10 days under the selected labels; other durations depend on site, pathogen, source control and response. Renal disease does not require a routine systemic dose modification, but AKI risk remains. Severe liver disease warrants periodic enzymes; the labels’ limited accumulation observations do not establish one universal hepatic schedule.

Systemic products are contraindicated with prior clindamycin or lincomycin hypersensitivity. Cleocin T and vaginal cream additionally contraindicate a history of regional enteritis, ulcerative colitis or antibiotic-associated colitis; vaginal cream also includes its excipient allergy. Systemic labels advise caution with prior GI disease/colitis, rather than listing those histories identically as formal contraindications.

The selected oral capsules, pediatric oral solution and injection labels carry a boxed warning for severe C. difficile diarrhea/colitis and reserve systemic treatment for appropriate serious bacterial infections. The selected Cleocin T and vaginal cream labels have prominent colitis warnings but no boxed warning. Route-specific risks remain even without a box.

Systemic effects include diarrhea, nausea, abdominal symptoms, rash, liver-test abnormalities, blood-count changes and AKI; severe colitis and allergy can occur. Capsules can cause esophageal injury; injections can cause pain/sterile abscess or thrombophlebitis. Dermal products may burn, itch, dry or irritate skin; vaginal cream may cause candidiasis/vaginitis or local discomfort. Reported reactions and different-route trials do not share one reliable frequency.

Strong CYP3A4 inhibitors may increase systemic clindamycin levels; monitor adverse effects. Strong inducers such as rifampicin may reduce efficacy; monitor response. Clindamycin has neuromuscular-blocking effects that can enhance anesthetic muscle blockers; communicate exposure before procedures. The dermal and vaginal labels also include this blocking-agent caution.

The selected injection label lists physical incompatibility with ampicillin sodium, phenytoin sodium, barbiturates, aminophylline, calcium gluconate and magnesium sulfate. Verify the actual concentration, diluent and line before mixing. Do not add medicines to a GALAXY premix or connect these plastic containers in series; inappropriate series use can cause air embolism.

The Cleocin cream label advises avoiding latex/rubber condoms or diaphragms within 72 hours after treatment; CDC’s BV page gives a 5-day caution for clindamycin cream. Use the more conservative 5-day barrier-avoidance advice and obtain an appropriate protection plan; these products differ from ovules or single-dose creams. For acne, use prescribed benzoyl peroxide alongside antibiotic treatment to limit resistance; this does not convert a single-agent label into fixed-combination instructions.

Systemic labels report no increased congenital-abnormality frequency in second/third-trimester clinical experience; first-trimester adequate studies are lacking and use should be clearly needed. Selected vaginal cream is labeled for nonpregnant and second/third-trimester patients; its first-trimester precaution requires benefits to outweigh risks. CDC recommends treating symptomatic BV in pregnancy and permits its recommended clindamycin-cream regimen. Assess the actual product and indication rather than declare every route risk-free.

Oral/IV clindamycin appears in milk and may affect infant GI flora. Required treatment is not by itself a reason to stop breastfeeding, but an alternative may be preferred; watch for diarrhea, thrush/diaper rash or rarely blood in stool. Milk levels after dermal/vaginal use are not established in those labels; weigh need and infant risk. Avoid infant ingestion of Cleocin T applied to the chest.

Choose oral liquid when exact weight dosing or swallowing prevents capsule use. Monitor organ function during pediatric systemic treatment. Selected preservative-containing injection requires particular neonatal caution; this profile does not provide an unambiguous PMA-boundary protocol. Cleocin T safety/effectiveness below 12 and vaginal-cream pediatric safety/effectiveness are not established. Older or severely ill patients may tolerate diarrhea poorly and have more severe C. difficile disease.

Systemic renal dose modification is not routinely required, and dialysis does not effectively remove clindamycin. Nonetheless, nephrotoxicity requires renal surveillance when risk factors exist. Moderate/severe liver disease can prolong half-life; monitor severe hepatic disease and adjust clinically rather than treat limited every-8-hour accumulation observations as an all-route guarantee. The topical/vaginal labels give no numerical organ-adjustment algorithms.

Clindamycin binds bacterial 23S RNA in the 50S ribosomal subunit and inhibits protein synthesis. Ribosomal modification can cause constitutive or inducible resistance, with cross-resistance among lincosamides, macrolides and streptogramin B. Labels advise testing macrolide-resistant staphylococci and beta-hemolytic streptococci for inducible clindamycin resistance. Do not assume all MRSA isolates are susceptible.

Oral clindamycin is well absorbed; food does not materially reduce absorption. Systemic half-life averages about 2.4 hours in healthy adults. It distributes into tissues and bone but inadequately into CSF, and CYP3A4/3A5 contribute to metabolism. Phosphate and palmitate forms become active clindamycin in vivo. Selected dermal solution studies measured low serum levels; vaginal cream studies found approximately 5% systemic absorption. Neither local route establishes zero colitis risk.

Follow infection response and susceptibility, plus source control where indicated. During prolonged systemic therapy obtain periodic CBC, liver and kidney tests; check renal function especially with renal dysfunction/nephrotoxins. Monitor bowel changes during and after every route, and evaluate recurrent vaginal symptoms rather than repeatedly self-treat. Current C. difficile treatment algorithms are outside this profile; older topical-label vancomycin schedules are not propagated.

Take systemic treatment exactly as prescribed; report significant/watery/bloody diarrhea, fever or cramps promptly even months afterward. Swallow capsules with the specified water/upright precautions; measure liquid in mL. Protect eyes with local products; rinse accidental exposure with water. Shake topical lotion immediately before use; avoid fire/flame/smoking during and immediately after solution application. Vaginal applicators are filled to their stop, used for one dose and discarded; observe intercourse/product/barrier restrictions.

Seek medical or Poison Control advice after overdose, a wrong-route dose or an IV infusion error; severe allergy, cardiovascular symptoms or marked illness requires emergency treatment. Local products can produce systemic effects when excessively absorbed. Hemodialysis/peritoneal dialysis are ineffective at removing clindamycin. Never give concentrated vial solution as an IV push.

Product

Cleocin HCl 300 mg capsule

Route

Oral; prescription only

Appearance

Light blue capsule; CLEOCIN 300 mg

Example package

100 capsules · NDC 0009-0395-14

Reviewed: capsules 75/150/300 mg; palmitate oral solution 75 mg/5 mL after reconstitution; phosphate concentrated vials 150 mg/mL, IV ADD-Vantage vials and GALAXY 300/600/900 mg in 50 mL premixes. Cleocin T solution/lotion is 10 mg/mL; gel 10 mg/g. Vaginal cream is 2%, delivering about 100 mg clindamycin equivalent per 5 g applicator; 40 g tube with 7 disposable applicators, NDC 0009-3448-01. These formulations are not interchangeable by volume.

Capsules, selected concentrated injection and local products: controlled room temperature 20–25°C. Topical and vaginal products: protect from freezing; tightly close liquid topical containers and keep flammable solution away from heat/sparks/flame. Oral granules: add 75 mL water in portions to yield 100 mL, shaking to uniformity; keep reconstituted solution at room temperature, not refrigerated, for 2 weeks. GALAXY premix: room temperature 25°C, avoid above 30°C, verify clear solution/intact seal/no leak, and add no medicines. Pharmacy bulk injection is not for direct infusion; use/discard remaining contents within 24 hours after first entry under the specified aseptic pharmacy conditions. Chemical admixture stability is not a sterile beyond-use authorization.